ANGIOGRAPHIC LESION SIZE ASSOCIATED WITH LOC387715 A69S GENOTYPE IN SUBFOVEAL POLYPOIDAL CHOROIDAL VASCULOPATHY

Purpose: To investigate whether the LOC387715/ARMS2 variants are associated with an angiographic phenotype, including lesion size and composition, in subfoveal polypoidal choroidal vasculopathy. Methods: Ninety-two subjects with symptomatic subfoveal polypoidal choroidal vasculopathy, whose visual acuity was from 0.1 to 0.5 on the Landolt chart, were genotyped for the LOC387715 polymorphism (rs10490924) using denaturing high-performance chromatography. The angiographic phenotype, including lesion composition and size, was evaluated by evaluators who were masked for the genotype. Lesion size was assessed by the greatest linear dimension based on fluorescein or indocyanine green angiography. Results: Although there was no statistically significant difference in lesion size on indocyanine green angiography (P = 0.36, Kruskal-Wallis test) and in lesion composition (P = 0.59, chi-square test) among the 3 genotypes, there was a statistically significant difference in lesion size on fluorescein angiography (P = 0.0022, Kruskal-Wallis test). Conclusion: The LOC387715 A69S genotype is not associated with lesion composition or size on indocyanine green angiography but with lesion size on fluorescein angiography in patients with subfoveal polypoidal choroidal vasculopathy. Because fluorescein angiography findings represent secondary exudative changes, including subretinal hemorrhages and retinal pigment epithelial detachment, the results in the present study likely indicate that the T allele at the LOC387715 gene is associated with the exudative activity of polypoidal lesions.

[1]  Y. Tano,et al.  One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. , 2010, Ophthalmology.

[2]  H. Iijima,et al.  Association of LOC387715 A69S with vitreous hemorrhage in polypoidal choroidal vasculopathy. , 2008, American journal of ophthalmology.

[3]  F. Tsai,et al.  HTRA1 POLYMORPHISM IN DRY AND WET AGE-RELATED MACULAR DEGENERATION , 2008, Retina.

[4]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[5]  Akira Negi,et al.  LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population. , 2007, American journal of ophthalmology.

[6]  Michael D. Ober,et al.  SELECTIVE PHOTODYNAMIC THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH POLYPOIDAL CHOROIDAL NEOVASCULARIZATION , 2007, Retina.

[7]  M. Brantley,et al.  Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration. , 2007, American journal of ophthalmology.

[8]  A. Tsujikawa,et al.  Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. , 2007, American journal of ophthalmology.

[9]  I. Maruko,et al.  Clinical characteristics of exudative age-related macular degeneration in Japanese patients. , 2007, American journal of ophthalmology.

[10]  H. Imaizumi,et al.  Photodynamic Therapy for Age-Related Macular Degeneration in Japanese Patients: Results After One Year , 2007, Japanese Journal of Ophthalmology.

[11]  J. Haines,et al.  Phenotype analysis of patients with the risk variant LOC387715 (A69S) in age-related macular degeneration. , 2007, American journal of ophthalmology.

[12]  B. Rosner,et al.  Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. , 2007, JAMA.

[13]  W. März,et al.  Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. , 2007, Ophthalmology.

[14]  Y. Tano,et al.  Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[15]  M. Mandai,et al.  HEMORRHAGIC COMPLICATIONS AFTER PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY , 2007, Retina.

[16]  H. Kawakami,et al.  A polymorphism of LOC387715 gene is associated with age-related macular degeneration in the Japanese population , 2007, Neuroscience Letters.

[17]  Chi Pui Pang,et al.  HTRA1 promoter polymorphism in wet age-related macular degeneration. , 2007, Science.

[18]  N. Camp,et al.  A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration , 2006, Science.

[19]  S. Fisher,et al.  Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk , 2005 .

[20]  T. Iida [Diagnostic criteria for polypoidal choroidal vasculopathy and their clinical significance]. , 2005, Nippon Ganka Gakkai zasshi.

[21]  J. Cunha-Vaz,et al.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[22]  S. Natarajan,et al.  Role of photodynamic therapy in polypoidal choroidal vasculopathy. , 2005, Indian journal of ophthalmology.

[23]  T. Lai,et al.  Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. , 2004, Ophthalmology.

[24]  N. Bressler Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. , 2003, American journal of ophthalmology.

[25]  M. Matsumura,et al.  Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. , 2003, Archives of ophthalmology.

[26]  Michael Stur,et al.  Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. , 2003, American journal of ophthalmology.

[27]  J. Slakter,et al.  TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY WITH PHOTODYNAMIC THERAPY , 2002, Retina.

[28]  L. Yannuzzi,et al.  Idiopathic polypoidal choroidal vasculopathy of the macula. , 1998, Ophthalmology.

[29]  L. Yannuzzi,et al.  The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. , 1997, Archives of ophthalmology.

[30]  Lars G Fritsche,et al.  Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. , 2005, Human molecular genetics.

[31]  J. Slakter,et al.  INDOCYANINE GREEN VIDEOANGIOGRAPHY OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY , 1995, Retina.

[32]  L A Yannuzzi,et al.  IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV) , 1990, Retina.